Jump Financial’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Jump Financial’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36,120	Closed	-$3.97M	–	2176
2022 Q4	$3.97M	Buy	+36,120	New	+$2.34M	0.21%	134
2022 Q3	–	Sell	-19,200	Closed	-$542K	–	2114
2022 Q2	$542K	Buy	+19,200	New	+$556K	0.02%	823
2022 Q1	–	Sell	-5,802	Closed	-$229K	–	2032
2021 Q4	$229K	Buy	+5,802	New	+$182K	0.01%	1042
2021 Q3	–	Sell	-10,311	Closed	-$253K	–	1621
2021 Q2	$253K	Buy	+10,311	New	+$230K	0.02%	745

Other funds holding RXDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jump Financial's RXDX Position: Q1 2023 in Review

Jump Financial sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 36,120 shares — an estimated $3.97M sold.

Jump Financial first reported a position in RXDX in Q2 2021 and held it in 4 quarters. The position peaked at $3.97M in Q4 2022. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

Jump Financial reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Jump Financial sold 36,120 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $3.97M.
Jump Financial first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
Jump Financial's Prometheus Biosciences, Inc. Common Stock position peaked at $3.97M in Q4 2022.
219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on Jump Financial's 13F filing for Q1 2023, filed 3 May 2023.